Can Botulinum Toxin Decrease Carer Burden in Long Term Care Residents With Upper Limb Spasticity? A Randomized Controlled Study

Journal of the American Medical Directors Association

Volumn 13, Issue 5, 2012, Pages 477-484

  Lam, Kuen ^a   Lau, Kwok Kwong ^b   So, Kar Kui ^b   Tam, Cheuk Kwan ^c   Wu, Yee Ming ^d   Cheung, Gloria ^d   Liang, Ka Shing ^e   Yeung, Kwan Mo ^b   Lam, Kin Yip ^f   Yui, Samuel ^a   Leung, Christine ^a  

^a Cheshire Home   (Hong Kong)

^b PRINCESS MARGARET HOSPITAL   (Hong Kong)

^c TWGHs Wong Tai Sin Hospital   (Hong Kong)

^d Haven of Hope Hospital   (Hong Kong)

^e SHATIN HOSPITAL   (Hong Kong)

^f KWONG WAH HOSPITAL   (Hong Kong)

Author keywords

Botulinum toxin; Carer burden; Long term care; Spasticity

Indexed keywords

BOTULINUM TOXIN A; SODIUM CHLORIDE;

ABDUCTION; AGED; ARM DISEASE; ARTICLE; BICEPS BRACHII MUSCLE; CAREGIVER BURDEN; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EDEMA; ELBOW; FEMALE; FEVER; FINGER; GOAL ATTAINMENT; HUMAN; HUMERUS FRACTURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NURSING HOME PATIENT; OCCUPATIONAL THERAPY; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PATIENT CARE; PHYSIOTHERAPY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; SCORING SYSTEM; SHOULDER; SPASTICITY;

EID: 84861686571     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2012.03.005     Document Type: Article

References (24)

1. Wagner L.M., Clevenger C. Contractures in nursing home residents. J Am Med Dir Assoc 2010, 11:94-99.
2. Wong T.C., Wu W.C., Cheng H.S., et al. Spontaneous fractures in nursing home residents. Hong Kong Med J 2007, 13:427-429.
3. Takamoto S., Saeki S., Yabumoto Y., et al. Spontaneous fractures of long bones associated with joint contractures in bedridden elderly inpatients: Clinical features and outcome. Am Geriatr Soc 2005, 53:1439-1441.
4. Knight D.B., Scott H. Contracture and pressure necrosis. Ostomy Wound Manage 1990, 26:60-62. 65-67.
5. Steffen T.M., Mollinger L.A. Low-load, prolonged stretch in the treatment of knee flexion contractures in nursing home residents. Phys Ther 1995, 75:886-895. discussion 895-897.
6. Katalinic O.M., Harvey L.A., Herbert R.D., et al. Stretch for the treatment and prevention of contractures. Cochrane Database Syst Rev 2010, (9):CD007455.
7. Montane E., Vallano A., Laporte J.R. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. Neurology 2004, 63:1357-1363.
8. Kita M., Goodkin D.E. Drugs used to treat spasticity. Drugs 2000, 59:487-495.
9. Esquenazi A., Novak I., Sheean G., et al. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments-introduction. Eur J Neurol 2010, 17:1-8.
10. Bhakta B.B., Cozens J.A., Chamberlain M.A., et al. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: A randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000, 69:217-221.
11. Simpson D.M., Gracies J.M., Graham H.K., et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1691-1698. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
12. Bohannon R.W., Smith M.B. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987, 67:206-207.
13. Bhakta B.B., Cozens J.A., Bamford J.M., et al. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996, 61:30-35.
14. Ashford S., Turner-Stokes L. Goal attainment for spasticity management using botulinum toxin. Physiother Res Int 2006, 11:24-34.
15. Haugh A.B., Pandyan A.D., Johnson G.R. A systematic review of the Tardieu Scale for the measurement of spasticity. Disabil Rehabil 2006, 28:899-907.
16. Warden V., Hurley A.C., Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc 2003, 4:9-15.
17. Dowding C.H., Shenton C.L., Salek S.S. A review of the health-related quality of life and economic impact of Parkinson's disease. Drugs Aging 2006, 23:693-721.
18. Khan F., McPhail T., Brand C., et al. Multiple sclerosis: Disability profile and quality of life in an Australian community cohort. Int J Rehabil Res 2006, 29:87-96.
19. Sheean G., Lannin N.A., Turner-Stokes L., et al. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: International consensus statement. Eur J Neurol 2010, 17:74-93.
20. McCrory P., Turner-Stokes L., Baguley I.J., et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: A multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med 2009, 41:536-544.
21. Shaw L.C., Price C.I., van Wijck F.M., et al. Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial: Effect on impairment, activity limitation, and pain. Stroke 2011, 42:1371-1379.
22. Sheean G. The treatment of musculoskeletal pain and spasm with botulinum toxin. Curr Pain Headache Rep 2002, 6:460-469.
23. Rosales R.L., Kanovsky P., Fernandez H.H. What's the " catch" in upper-limb post-stroke spasticity: Expanding the role of botulinum toxin applications. Parkinsonism Relat Disord 2011, 17. S3-10.
24. Suputtitada A., Suwanwela N.C. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil 2005, 27:176-184.